Dyne Therapeutics (Dyne Therapeutics) GF Value Rank : 0 (As of May. 02, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics GF Value Rank?

Dyne Therapeutics has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Dyne Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyne Therapeutics (Dyne Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Trapelo Road, Waltham, MA, USA, 02451

Website

https://www.dyne-tx.com

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

Executives

Dirk Kersten	director, 10 percent owner	C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Joshua T Brumm	director, officer: See Remarks	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Jonathan Mcneill	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Oxana Beskrovnaya	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Richard William Scalzo	officer: See Remarks	25 ALBERTA LANE, HOLLISTON MA 01746
Wildon Farwell	officer: Chief Medical Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Susanna Gatti High	officer: Chief Operating Officer	75 LORIMER ROAD, BELMONT MA 02141
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Jason P Rhodes	director, 10 percent owner	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Carlo Incerti	director	FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Romesh Subramanian	10 percent owner, officer: Chief Scientific Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Cureduchenne Ventures, Llc	10 percent owner	1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660